Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

✍ Scribed by Richard E. Nettles; Min Gao; Marc Bifano; Ellen Chung; Anna Persson; Thomas C. Marbury; Ronald Goldwater; Michael P. DeMicco; Maribel Rodriguez-Torres; Apinya Vutikullird; Ernesto Fuentes; Eric Lawitz; Juan Carlos Lopez-Talavera; Dennis M. Grasela

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 282 KB
• Volume: 54
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.24609

✦ Synopsis

Abbreviations: AE, adverse event; AUC, area under the plasma concentration time curve; AUC (TAU) , AUC over 12-hour dosing interval for 30 mg twice daily; C min , minimum observed plasma concentration; C max , maximum observed plasma concentration; C trough , trough concentrations; CLT/F, apparent total body clearance; CV, coefficient of variation; DAA, direct-acting antiviral; ECG, electrocardiogram; HCV, hepatitis C virus; ISG, interferon-stimulated gene; NS5A, nonstructural protein 5A; PCR, polymerase chain reaction; PEG-IFN, pegylated interferon; PK, pharmacokinetics; daily; RBV, ribavirin; T max , time of maximum observed plasma concentration; T 1/2 , half life.